MarketPulse

NDA

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Faces Securities Fraud Class Action Over Relacorilant FDA Claims

Class action lawsuit filed against $CORP alleging false statements about relacorilant clinical trial strength and FDA approval prospects. Investors from Oct 2024-Dec 2025 urged to participate.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Suit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging misleading statements about FDA approval timeline for Anaphylm and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Hit With Securities Fraud Class Action Over Relacorilant Claims

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.
CORTsecurities fraudclass action lawsuit